Introduction
The intensity and duration of an inflammatory process depend upon the local balance between proand anti-inflammatory factors. Substances of neuronal origin have been the subject of considerable research because they exert specific effects on immune cells and can regulate inflammation 1, 2 .
In vivo studies of inflammatory diseases have shown that the synthesis of Nerve Growth Factor (NGF) is up-regulated in the cerebrospinal fluid of multiple sclerosis (MS) patients 3 and in the sera of systemic lupus erythematosus (SLE) patients 4 . A growing number of studies on inflammatory diseases have demonstrated that the inflammatory state is characterized by upregulation of NGF synthesis 5, 6 . Numerous cytokines such as IL-1β, TNF-α and IL-6 can induce NGF production in fibroblasts, endothelial cells, and glial cells [7] [8] [9] . In addition, immune cells involved in innate and acquired immunity show a basal expression of NGF, whose synthesis is enhanced after stimulation with specific antigens and cytokines [10] [11] [12] [13] [14] [15] . The immune cells that produce NGF also express the specific NGF receptor TrkA 16 which, on binding to its ligand, activates intracellular pathways and nuclear factors [17] [18] [19] [20] , in a manner similar to what happens in neuronal cells 21 . In vitro, the administration of NGF to purified myeloid or lymphoid cell populations influences a wide range of functions: the release of inflammatory mediators, chemotaxis, the production of cytokines and immunoglobulins, proliferation, survival (for a review see Aloe et al. 22 ).
In spite of the large number of studies on the in vitro effects of NGF, it is still not clear why NGF is produced in vivo during the inflammation process and how its local synthesis, often in an autocrine fashion, can influence the ongoing immune response.
Our recent results on autocrine NGF synthesis in B-lymphocytes, which directly regulate the expression and release in these cells 23 of calcitonin gene-related peptide (CGRP), a neuropeptide able to inhibit immune response, indicate that NGF may have an anti-inflammatory action.
Specific receptors for CGRP are present in T-and B-lymphocytes and in macrophages [24] [25] [26] [27] , and
several in vitro studies have demonstrated that CGRP is a potent inhibitor of mitogen and antigenstimulated proliferation of T-cells [28] [29] [30] [31] , and of antigen presentation by macrophages 32, 33 . In vivo data indicate an anti-inflammatory action of CGRP, since its administration inhibits edema formation induced by inflammatory mediators, prevents the induction of contact hypersensitivity, and influences the migration of monocytes and antigen presentation [34] [35] [36] .
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Thus NGF may influence the inflammatory process either directly, by regulating immune cell functions, or indirectly, by modulating CGRP synthesis, which in turn affects the immune response. To test this hypothesis we investigated whether NGF can regulate the synthesis of CGRP in monocytes. These antigen-presenting cells express TrkA receptors 37 . In agreement with earlier findings in macrophages 15 , we found that monocytes synthesize basal levels of NGF and, after LPS stimulation, up-regulate NGF expression. We also observed that endogenous NGF affects CGRP and IL-10 synthesis, as well as the expression of molecules involved in T-cell activation, and that these effects can be partially mimicked using a CGRP 1 receptor antagonist.
Materials and Methods Chemicals
LPS from E. coli serotype O55: B5 was purchased from Sigma (St. Louis, MO). NGF was purified according to Bocchini and Angeletti 38 and NGF antibodies were raised in rabbit or goat and purified by affinity chromatography as described by Stoeckel et al. 39 Purified rabbit and goat IgG were from Zymed Laboratories Inc.(San Francisco, CA). TrkA polyclonal antibody, specific for an intracellular domain of the receptor, was from Santa Cruz Biotechnology (Santa Cruz, CA). The polyclonal antibody against human CGRP was from Peninsula Laboratories (Bachem Group, San
Carlos, CA), as was the CGRP antagonist, CGRP . For the flow cytometry study the fluoresceine isothiocyanate (FITC) and phycoerythrin (PE) conjugated monoclonal antibodies and their isotype controls were from Pharmingen (BD Biosciences Europe, Erembodegem, Belgium) (CD80 and CD86) and from Caltag Laboratories (Burlingame, CA)(CD14 and HLA-DR).
Human monocyte cultures
Peripheral blood mononuclear cells (PBMC) were obtained from buffy-coats, after centrifugation over Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) gradients. Monocytes were separated from lymphocytes by Percoll gradients as described by Sallusto and Lanzavecchia 40 , followed by immunomagnetic negative selection (Miltenyi Biotec, Germany). The purity of the preparations was assessed by flow cytometry and the fraction of CD14 positive cells was >95%.
Monocytes were plated at a concentration of 2x10 6 in 25 cm 2 tissue culture flasks (Nunc A/S, Denmark), cultured at 37°C in a humidified atmosphere enriched with 5% CO2 in RPMI 1640
(Biowhittaker, Walkersville, MD) with 50 Units/ml penicillin, 50 µg/ml streptomycin, 2mM Lonly.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From glutamine (all from Gibco-BRL Life Technology, Gaithersburg MD) and 10% heat-inactivated and endotoxin-free fetal calf serum (FCS) (HyClone Labs, Logan, Utah), with or without the addition of 100 ng/ml LPS, 100 ng/ml NGF, 10 µg/ml affinity-purified anti-NGF antibody (abNGF) raised in goat, 10 µg/ml purified goat IgG, 10µM of CGRP8-37, the CGRP antagonist (Peninsula Laboratories)
RNA extraction
Using the RNeasy® mini kit (Qiagen GmbH, Germany), total RNA was extracted from 5x10 6 cells for each treatment and time-point group (n=4). In brief, the cells were lysed using lysis buffer and then homogenized using QIAshredder™ columns (Qiagen). The homogenized lysate was diluted 1:1 v/v with ethanol 70% and centrifuged through RNeasy mini-columns. To eliminate any genomic DNA contamination before in vitro synthesis of the cDNA, the columns were treated with 1 unit/ml DNase (RNase free). After two washings the bound RNA was eluted in 40 µl of RNase-free water and the absorbance of all the extracted RNA was measured by spectrophotometer to determine the concentration and purity of the samples.
Reverse transcriptase-polymerase chain reaction
A semi-quantitative analysis of CGRP and NGF expression was performed as previously described 23, 41 . In brief, two µg of total RNA for each sample were incubated with 1µg oligo dT 
Analysis of PCR products
PCR products were electrophoresed in 2% agarose gel together with DNA ladder of 100 base pairs (Gibco) and visualized by ethidium bromide. For the Southern blotting, the cDNA was transferred to nylon membranes and the blot was hybridized at 55°C with a radiolabelled oligonucleotide probe (5'-AAGCCTGCCAGCCGATGAGTCACACAGGTG-3') that recognized the CGRP coding sequence on exon 5, common to CGRP I e II genes. The hybridized membranes were washed at 55°C, twice in 2xSSC for 15 min, 1xSSC containing 0.1%SDS for 15 min and 0.1xSSC containing 0.1%SDS for 15 min. Autoradiography was performed at -80°C with intensifying screening overnight.
Real-time PCR analysis
Total RNA was extracted from monocytes using Trizol reagent (Sigma) according to the manufacturer's instructions. In brief, 10x10 6 To obtain the expression rate, the CGRP mRNA was normalized with that of GAPDH. The results were expressed as fold increase in arbitrary units. confocal microscopy using a TCS Confocal System (Leica, Germany).
Flow cytometer analysis

IL-10 ELISA Determination
Conditioned media were collected from monocytes obtained from different donors (n=6) after 24 hours of incubation with LPS with or without the addition of anti-NGF antibodies, purified IgG and CGRP . After the addition of 1µl/ml of 0,2 mM PMSF to inhibit proteases, the media were stocked at -70°C and different experiments were analyzed at the same time using an IL-10 ELISA Kit (BioSource International, Nivelles, Belgium) following the manufacturer's instructions. The sensitivity of the assay was 5 pg/ml.
Statistical analysis
Statistical analysis of the results was performed using a two-way analysis of variance (ANOVA)
followed by post-hoc Tukey-Kramer test for multiple comparisons.
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Results
CGRP expression in monocytes
Total RNA was extracted from freshly-isolated human monocytes and in vitro-activated monocytes (n=4), and reverse-transcribed in cDNA. After PCR amplification using specific exon 5 CGRP primers that recognize homologous regions of human CGRP I and II genes, the products were visualized on ethidium bromide-stained gels. Low levels of CGRP gene transcripts were detected in monocytes freshly isolated from blood or after 24 hours in culture without any specific stimulation (Us). After 24 hours of LPS stimulation of monocytes, the CGRP expression was enhanced ( Figure 1A 
NGF regulates CGRP expression in monocytes
Similarly to other findings in macrophages 15 , LPS stimulation enhances NGF mRNA levels in quiescent monocytes ( Figure 3 ). Since CGRP expression is under NGF control in peripheral neurons 45, 46 , we investigated whether deprivation of endogenous NGF or the addition of exogenous NGF could influence the expression of CGRP in monocytes.
To neutralize the endogenous NGF produced by monocytes, we treated the cells with 10µg/ml anti-NGF antibodies. As shown in Figure 1A , after anti-NGF antibody treatment the expression of CGRP mRNA decreased in LPS-stimulated monocytes at 24 hours, while the addition of purified IgG did not modify CGRP expression ( Figure 1A ). The inhibitory effect of anti-NGF antibodies on CGRP expression induced by LPS stimulation was further confirmed by real-time PCR analysis (see Figure 4A) .
For 
Effects of NGF and CGRP deprivation on monocyte functions.
It is known that exogenous CGRP can affect antigen-presenting cell (APC) populations by acting directly on antigen presentation 32 , particularly co-stimulatory molecules 33 . In order to study the possible functional effects of the endogenous synthesis of NGF and CGRP, the expression of costimulatory molecules B7.1 (CD80) and B7. Table 1 and Figure 5 ).
The effects of NGF deprivation on HLA-DR expression were also investigated in LPS-stimulated monocytes (n=6). Treatment with anti-NGF antibodies resulted in a significant increase (p<0.05)
in HLA-DR expression in LPS-stimulated monocytes when compared with IgG-treated cells. A similar increase in the expression of HLA-DR was observed after incubating LPS-stimulated monocytes with 10µM of CGRP (Fig.6 ).
Since in monocytes LPS stimulation induces the synthesis of IL-10, which in turn can affect either HLA-DR 47 or B7 expression 48 , the conditioned media of previous experiments (n=6) were only.
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The CGRP 1 receptor antagonist was not effective in reducing the IL-10 concentration in LPStreated monocytes (data not shown).
Discussion
The results of the present study show that, similarly to other antigen-presenting cells 23, 49 , human monocytes are able to synthesize CGRP, and that CGRP expression is enhanced after LPS stimulation. In addition, we show for the first time that endogenous CGRP synthesis in monocytes is regulated by NGF. Since monocytes produce their own NGF and its synthesis is up-regulated on activation, we found that the neutralization of endogenous NGF using anti-NGF antibodies markedly reduces the synthesis of CGRP induced by LPS.
This regulation of CGRP expression by NGF is also supported by the finding that in vitro,
after the addition of exogenous NGF, the enhancement of NGF concentration can modify CGRP production in unstimulated monocytes but does not influence CGRP expression in LPS-treated cells, which already have an up-regulated endogenous synthesis of NGF.
These data confirm our previous results in human B-lymphocytes. In these cells, as now similarly observed in monocytes, the enhanced autocrine synthesis of NGF regulates CGRP synthesis 23 after specific stimulation.
The NGF control of CGRP expression seems to be a mechanism common to immune cells as well as to the peripheral sensory neurons in which it was first described 45, 46 58, 59 , as well as HLA-DR 48 . In our study we show for the first time that the described LPSinduced reduction in CD86 and HLA-DR expression in human monocytes 48, 58, 60 It has been suggested that CD80 and CD86 play a key role in immune activation, tolerance regulation and skewing of T-helper immune responses in a number of disease models 61, 62 and alteration of their expression can have profound effects on the development of immune responses [63] [64] [65] . CD80 and CD86 act as ligands for CD28 and CTLA-4 (now known as CD152) receptors expressed on T-lymphocytes and while the binding with CD28 promotes T-cell activation, binding with CD152 inhibits the T-cell response 66 . Although a number of studies have shown that the selective blocking of CD80 or CD86 differentially influences the immune response [63] [64] [65] , it is still a matter of debate whether they mediate redundant signals or have distinct regulatory functions 67 .
Recent findings have suggested that CD80 and CD86 are not interchangeable co-stimulators, which merely show different kinetics of expression, but that they selectively bind to their receptors and that CD80 is a more potent ligand for CD152 68 .
only. Furthermore, in septic patients, characterized by decreased MHC class II molecule expression in monocytes 70, 71 , CGRP plasma levels are greatly enhanced and the highest levels are associated with a lethal outcome 72 . These findings, together with our in vitro data, suggest that CGRP could be a key mediator of the LPS-induced responses.
The interaction between endogenous NGF and CGRP and the synthesis of IL-10 in LPSactivated monocytes was also investigated.
Our data show that, while enhancing HLA-DR and CD86 expression, the inhibition of endogenous NGF resulted in a significant decrease in the concentration of IL-10 in the conditioned media. This finding is consistent with findings in EAE models and in in vitro cultures of microglial cells showing that the administration of exogenous NGF induces the synthesis of IL-10 73,74 and changes in B7 expression 75 . Induction of IL-10 synthesis is a well-described monocyte response to LPS 76 and involves the activation of p38 MAPK 77 , a protein kinase also regulated by the signal transduction pathways activated by the binding of NGF to TrkA in NGF-responsive cells 21, 78 . As endogenous NGF neutralization results in decreased IL-10 synthesis, it is probable that NGF is directly involved in the regulation of IL-10 production in LPS-stimulated monocytes.
This hypothesis is supported by findings in epithelial cells 79 showing that NGF has a dosedependent effect on IL-10 mRNA expression and protein production.
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Interestingly, pre-administration of the CGRP 1 receptor antagonist did not result in a significant inhibition of IL-10 synthesis in LPS-stimulated monocytes. This suggests that the effect of NGF on IL-10 production is not mediated by the endogenous CGRP synthesis. Our results are supported by previous studies showing that SAC-stimulated mononuclear cells 33 and LPS-activated Langherans cells 80 enhance their endogenous synthesis of IL-10 following exogenous addition of CGRP, while CGRP 8-37 treatment has no effect on IL-10 synthesis induced by LPS activation 80 , similarly to what we found in our experimental conditions. Similar results have been obtained in in vivo studies when using exogenous CGRP or when blocking endogenous CGRP production with the CGRP 1 receptor antagonist. The intra-cutaneous injection of CGRP in mice promotes hapten-specific tolerance and enhances IL-10 production 35, 81 . As ultraviolet treatment increases the number of CGRP nerve fibers and the CGRP content 82 in the skin of mice, the use of CGRP 8-37 before hapten-sensitization only partially reduces immunosuppression 81, 82 .
We cannot rule out the possibility that other newly-described receptors 83 may be involved in the control of endogenous CGRP functions, thus explaining the lack of action by CGRP .
On the other hand, both exogenous 56 Recently, topical applications of NGF have been successfully used for the clinical treatment of human immune corneal ulcers and pressure ulcers 88, 89 .
However, because of the wide range of effects that NGF can have on the nervous, endocrine and immune systems 2 , its therapeutic use has been limited. One of the key findings of the present study is that induction of CGRP synthesis by NGF seems to be responsible, at least in part, for the effects of NGF in monocytes. HLA-DR expression was measured by flow cytometry analysis in LPS-stimulated monocytes after 24 hours of treatement with anti-NGF antibodies, control IgG and CGRP . NGF neutralization induces a significant increase in the specific HLA-DR immunoreactivity in LPS-stimulated monocytes and a similar enhancement in HLA-DR expression was observed also in LPS-stimulated cells after CGRP treatment. The data represent the mean of six independent experiments and the results were expressed as increments relative to the controls of mean fluorescence intensity ± standard error of the mean (LPS+aNGF vs LPS+IgG *p<0.05; LPS+CGRP8-37 vs LPS p<0.01 according to Tukey-Kramer test). 
